Key molecular biological pathways that drive changes in cells that cause Alzheimer’s disease have been revealed by scientists.
The team found that, while nearly all known pathways are involved in the disease, the biological mechanisms most frequently involved – including those involving the immune system Translation, metabolism and long-term depression – have not changed significantly in 30 years, despite major technological advances. The scientists’ work has been published in Frontiers in the Neuroscience of Aging.
Statistics of Alzheimer’s disease
Nearly six million older adults have Alzheimer’s disease in the United States, a number that is expected to double by 2050. Already the sixth leading cause of death, Alzheimer’s disease is a neurodegenerative disease. complex causes memory loss, confusion, poor judgment, depression, delusions and agitation that rob people of their ability to live independently.
‘Alzheimer’s disease is not only incredibly complex, but its pathology encompasses most of the known biological pathways. This means that the effects of the disease on the body are much broader than we realize. ‘
“The burden of Alzheimer’s disease is steadily increasing, pushing us forward,” said Winston A. Hide, PhD, director of the Precision RNA Medicine Core Facility at BIDMC and an associate professor of medicine at Harvard Medical School. a nervous epidemic.
The team performed a comprehensive text search of 206,324 pathway-specific dementia abstracts published since 1990. Next, they looked at 341 known biological pathways and identified determine how many publications link a certain pathway to the disease.
Pathways in Alzheimer’s disease
The researchers found that 91% of the pathways – all but seven – are involved in Alzheimer’s disease. Nearly half of the pathways are involved in Alzheimer’s disease in more than 100 scientific papers.
They also found that the top 30-ranked pathways most mentioned in the literature have remained relatively consistent over the past 30 years, suggesting that most research on the disease has focused on one subgroup of all known disease-related pathways.
“Clinical trials aimed at delaying the onset or slowing the progression of Alzheimer’s disease have largely failed,” said first author Sarah Morgan, a postdoctoral researcher at BIDMC.
“Due to the unexpected diversity of pathways involved in Alzheimer’s disease, a wide range of disease processes have not been successfully targeted in clinical trials. We hypothesize that more comprehensive targeting of The underlying mechanisms involved in Alzheimer’s disease will increase the chances of success in future drug trials.”